{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:03:50Z","timestamp":1790795030774,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jacl.2016.04.013","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T13:00:26Z","timestamp":1462798826000},"page":"1011-1021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia"],"prefix":"10.1016","volume":"10","author":[{"given":"P. Barton","family":"Duell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget-Anne","family":"Kirwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3 Suppl","key":"10.1016\/j.jacl.2016.04.013_bib1","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","article-title":"Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Hopkins","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"19","key":"10.1016\/j.jacl.2016.04.013_bib2","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jacl.2016.04.013_bib3","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacl.2016.04.013_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/jgm.384","article-title":"A tetracycline-regulated adenoviral expression system for in\u00a0vivo delivery of transgenes to lung and liver","volume":"5","author":"Tietge","year":"2003","journal-title":"J Gene Med"},{"issue":"9719","key":"10.1016\/j.jacl.2016.04.013_bib5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jacl.2016.04.013_bib6","doi-asserted-by":"crossref","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.jacl.2016.04.013_bib7","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.jacl.2016.04.013_bib8","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacl.2016.04.013_bib9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2016.04.013_bib10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9753","key":"10.1016\/j.jacl.2016.04.013_bib11","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.jacl.2016.04.013_bib12","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacl.2016.04.013_bib13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM198709173171204","article-title":"Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia","volume":"317","author":"Hobbs","year":"1987","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jacl.2016.04.013_bib14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/CIRCULATIONAHA.107.753152","article-title":"Evidence mandating earlier and more aggressive treatment of hypercholesterolemia","volume":"118","author":"Steinberg","year":"2008","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacl.2016.04.013_bib15","first-page":"774","article-title":"PCSK9 Inhibitors and Cardiovascular Events","volume":"373","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jacl.2016.04.013_bib16","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jacl.2016.04.013_bib17","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global\u00a0Health Outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2016.04.013_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2016.04.013_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.jacl.2016.04.013_bib20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM199010043231404","article-title":"Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)","volume":"323","author":"Buchwald","year":"1990","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jacl.2016.04.013_bib21","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jacl.2016.04.013_bib22","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.jacl.2016.04.013_bib23","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jacl.2016.04.013_bib24","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMe1507041","article-title":"Proof that lower is better\u2013LDL cholesterol and IMPROVE-IT","volume":"372","author":"Jarcho","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2016.04.013_bib25","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.jacl.2016.04.013_bib26","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/j.jacl.2016.04.013_bib27","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.013_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/aor.12135","article-title":"Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?","volume":"38","author":"Rosada","year":"2014","journal-title":"Artif Organs"},{"issue":"8","key":"10.1016\/j.jacl.2016.04.013_bib29","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1194\/jlr.P027235","article-title":"Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia","volume":"53","author":"Arai","year":"2012","journal-title":"J Lipid Res"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287416302094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287416302094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T02:21:26Z","timestamp":1536718886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287416302094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1933287416302094"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2016.04.013","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2016.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}